The devastating loss of a young New Jersey mother of two has left her family not only grieving but also determined to shed ...

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on delivering therapeutics through effective oral delivery, announced today that it has received revised regulatory guidance for LPCN ...

SALT LAKE CITY - Lipocine Inc. (NASDAQ: NASDAQ:LPCN), a biopharmaceutical company with a market capitalization of approximately $24 million, announced today that it will conduct a phase 3 safety and ...

POSTPARTUM depression (PPD) affects 10–15% of individuals following childbirth, with higher prevalence observed in marginalised communities. Alarmingly, mental health conditions like PPD are now the ...

"I wish there was more open conversation around postpartum incontinence, along with real support—whether that’s access to ...

“Black women need to think about putting themselves first in their postpartum journey,” says Jakora Thompson, a 39-year-old ...

Nearly 50% of women who utilized antidepressant prescriptions before conception discontinued use after pregnancy without ...

The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point ...

This story first appeared in the Alabama Reflector. Last fall, Patricia called her counselor in a panic. A 29-year-old North Alabama mom, she was about to lose her Medicaid coverage, which was set to ...

Women who develop postpartum depression (PPD) may have distinct neuroactive steroid levels during the third trimester of pregnancy.

Almost all of the pregnant women Dr. Joshua Splinter sees at his rural East Texas practice are on Medicaid. For years, he ...

The findings of the study open the door to a potential preventive treatment for pregnant women whose blood tests reveal neuroactive steroid levels associated with an increased risk of postpartum ...